Work

Subcutaneous Immunoglobulin 16.5% (Cutaquig) in Primary Immunodeficiency Disease: Safety, Efficacy, and Patient Satisfaction with Modified Dosing Regimens

Year: 2023

Type: article

Study design: Clinical Trial

Source: Clinical Immunology

DOI: 10.1016/j.clim.2023.109402

Authors: Sudhir Gupta, James DeAngelo, Isaac Melamed, Jolan Walter, Ai-Lan Kobayashi, Tracy Bridges, J. Wesley Sublett, Jonathan Bernstein, Alan Koterba, Roger Kobayashi

Institutions: University of California, Irvine, University of Pittsburgh, IMMUNOe Research Center, University of South Florida, Massachusetts General Hospital, Johns Hopkins All Children's Hospital, University of California, Los Angeles, University of Cincinnati, Allergy Associates of the Palm Beaches

Language: English

Topic: Immunodeficiency and Autoimmune Disorders

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4377695859

FWCI:

Cites:

Cited by:

Related to: 10